Nucala (mepolizumab) logo

Product menu

Lungs science image

Discover Nucala (mepolizumab)

With up to 10 years of patient experience across 5 indications, totalling 618,000 patient years worldwide*1,2

Choose your indication

NA

COPD

NUCALA® is indicated as add-on maintenance treatment of adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) of an eosinophilic phenotype on a combination of an inhaled corticosteroid (ICS), a long-acting beta-2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA).1

Learn More
NA

Severe Asthma

NUCALA® is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. Nucala is also indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.1

Learn More

Abbreviations

COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist

References

* Based on worldwide usage of Nucala for all indications from 2015 to March 2025. Indications include: SEA, CRSwNP, EGPA and HES.1

  1. Nucala summary of product characteristics
  2. Pavord ID, et al. N Engl J Med. 2017;377(17):1613-1629

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UK_Safety@gsk.com.

March 2026 | PM-GB-MPL-WCNT-260004 (V1.0)